Business Wire

GRAI-MATTER-LABS

16.5.2022 09:02:11 CEST | Business Wire | Press release

Share
GrAI Matter Labs Unveils Life-Ready AI with GrAI VIP at GLOBAL INDUSTRIE

GrAI Matter Labs, a pioneer of brain-inspired ultra-low latency computing, announced today that it will be unveiling GrAI VIP, a full-stack AI system-on-chip platform, to partners and customers at GLOBAL INDUSTRIE, May 17th -20th , 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005226/en/

At GLOBAL INDUSTRIE, GML will demonstrate a live event-based, brain-inspired computing solution for purpose-built, efficient inference in a real-world application of robotics using the Life-Ready GrAI VIP chip. GrAI VIP is an industry-first near-sensor AI solution with 16-bit floating-point capability that achieves best-in-class performance with a low-power envelope. It opens up unparalleled applications that rely on understanding and transformations of signals produced by a multitude of sensors at the edge in Robotics, AR/VR, Smart Homes, Infotainment in automobiles and more.

“GrAI VIP is ready to deliver Life-Ready AI to industrial automation applications and revolutionize systems such as pick & place robots, cobots, and warehouse robots, as being demonstrated at the show,” said Ingolf Held, CEO of GrAI Matter Labs. “GrAI Matter Labs has a pipeline of over $1 Million in pre-orders, and we are thrilled to enable our early-access partners and customers in industrial automation, consumer electronics, defence and more, with our GrAI VIP M.2 cards sampling today.”

“GML is targeting the $1 billion+ fast-growing market (20%+ per year) of endpoint AI with a unique approach backed by innovative technology,” said Karl Freund, Founder and Principal Analyst at Cambrian-AI Research. “GML’s 'Life-Ready' AI provides solutions that here-to-fore were simply impossible at such low footprint and power.”

AI application developers looking for high fidelity and low latency responses for their edge algorithms can now get early access to the GrAI VIP platform and drive game-changing products in industrial automation, consumer electronics, and more.

About GrAI Matter Labs

At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans do. That makes machines assisting humans act, and react, in real-time, live. Which optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by an international team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye